Moderna Stock Jumps 6%: Q3 Profit Beats, Guidance Raised

Moderna shares rose more than 6% in premarket trading on Friday, November 6, 2026, after the biotech reported third-quarter revenue of $1.3 billion, swung to a $162 million profit, and raised its full-year revenue growth outlook to 15% to 25%. The result beat the $885.1 million analyst average by a wide margin and landed on a morning when investors were hunting for earnings strong enough to stand up after Thursday's technology rout.

What happened

Moderna reported total revenue of $1.3 billion for the third quarter of 2026, up 29% from $1.0 billion a year earlier. Net income was $162 million, compared with a net loss of about $200 million in the same quarter last year — a $362 million improvement. Diluted earnings per share were $0.38, compared with a loss of $0.51 a share a year earlier.

The beat was driven mainly by higher COVID vaccine sales in international markets, supported by deliveries under long-term strategic government partnerships. Revenue was $780 million in the United States and $533 million internationally, so the U.S. contributed about 60% of quarterly sales, according to the company's results and Reuters reporting.

Why it is blowing up

Three things made this more than a routine earnings beat. First, the scale of the miss to the upside: $1.3 billion against an $885.1 million average estimate compiled by LSEG is not a narrow beat. Second, Moderna did not just report a strong quarter — it raised what it expects for the whole year. Third, the stock had fallen in the previous session, so the premarket jump was a sharp reversal in sentiment in the middle of a fragile market.

Reuters noted that Moderna shares have surged more than eight-fold this year, mostly after the August announcement of trial success for its personalized cancer vaccine candidate, intismeran autogene, making the company one of the best performers in the S&P 500 this year. That run is why investors are testing whether sales, not just trial headlines, can support the move.

Key facts

• Revenue: $1.3 billion in Q3, up 29% year over year, versus the $885.1 million LSEG average estimate.
• Profit: Net income of $162 million, versus a $200 million loss a year earlier; diluted EPS of $0.38 versus -$0.51.
• Costs: Research and development spending fell 27% to $583 million, while cost of sales rose 54% to $318 million on higher product volume.
• Guidance raised: Full-year 2026 revenue growth is now expected at 15% to 25%, up from up to 10% previously.
• Cash outlook raised: Year-end cash and investments are now expected at $8.1 billion to $8.3 billion, up from $4.7 billion to $5.2 billion, helped by convertible-note financing proceeds; cash, cash equivalents and investments were $8.0 billion at September 30.
• Premarket reaction: Shares were up over 6% in premarket trading on Friday, according to Reuters.

Beyond COVID: the diversification story

Chief executive Stéphane Bancel pointed to the U.S. approval of mFLUSIVA, Moderna's flu vaccine and its fifth approved product globally. The FDA cleared it in August for adults aged 50 and older, though Moderna plans only a limited U.S. launch for 2026-27 because approval came after annual flu contracts were wrapped up.

In oncology, Moderna and Merck presented Phase 3 results in October showing intismeran combined with Keytruda reduced the risk of melanoma recurrence or death by 42%. The companies are working toward regulatory submissions, subject to approval. Moderna expects about half of full-year revenue internationally, underlining the importance of partnerships with the United Kingdom, Canada and Australia.

What is next

Moderna hosts its Analyst Day on November 12, 2026, where investors will look for detail on how durable international COVID demand is and what the next intismeran readouts show. None of that is guaranteed: guidance is a forecast, the cancer vaccine still needs approval, and a stock that has risen eight-fold this year can move sharply on any disappointment. This is not a recommendation to buy, sell or hold any security.

Sources

Reuters — Moderna lifts annual revenue forecast on strong COVID vaccine demand overseas
Moderna via Morningstar / ACCESS Newswire — Third Quarter 2026 Financial Results
TradingView News — Moderna rises as overseas COVID vaccine sales drive Q3 beat, guidance hike

FAQ

Why did Moderna stock rise on November 6, 2026?

Moderna beat expectations in Q3, swung to a profit, and raised its full-year outlook. Shares were up over 6% in premarket trading, according to Reuters.

How much revenue and profit did Moderna report in Q3 2026?

Revenue rose 29% to $1.3 billion, well above the $885.1 million LSEG average estimate. Net income was $162 million, or $0.38 per diluted share, versus a $200 million loss a year earlier.

What guidance did Moderna raise?

Moderna now expects total revenue growth of 15% to 25% in 2026, up from up to 10%, and year-end cash and investments of $8.1 billion to $8.3 billion, up from $4.7 billion to $5.2 billion.

What drove the revenue growth?

Higher COVID vaccine sales in international markets, supported by deliveries under long-term government partnerships. U.S. revenue was $780 million and international revenue was $533 million in the quarter.